Cardiac Risk Assessment Before Initiating Icotyde
Before starting Icotyde, screen all patients for traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia, obesity, smoking) and obtain a baseline echocardiogram if any cardiovascular risk factors or pre-existing cardiac disease are present 1.
Primary Risk Factors to Assess
While Icotyde is not a traditional cardiotoxic oncology agent, applying cardio-oncology risk stratification principles is prudent given its immune system modulation. Focus your assessment on:
Traditional Cardiovascular Risk Factors
- Hypertension - actively screen and document blood pressure
- Diabetes mellitus - check HbA1c and glucose control
- Dyslipidemia - obtain lipid panel
- Obesity - calculate BMI
- Active smoking - document current tobacco use 1
Pre-existing Cardiac Conditions
- Heart failure (systolic or diastolic) - particularly important as this carries the highest mortality risk (HR 1.34-1.38) in patients on immune-modulating therapies 2
- Atrial fibrillation/flutter - associated with 24% increased mortality risk 2
- Compromised left ventricular function - LVEF 50-55% or lower
- History of myocardial infarction
- Moderate or greater valvular heart disease 1
Age Consideration
Patients ≥60 years old are at increased risk for cardiovascular complications when receiving immune-modulating therapies 1.
Risk Stratification Algorithm
High-risk patients (require baseline echocardiogram):
- ≥2 traditional cardiovascular risk factors present
- Any pre-existing cardiac disease
- Age ≥60 years with ≥1 cardiovascular risk factor
Standard-risk patients (history and physical sufficient):
- 0-1 cardiovascular risk factors
- Age <60 years
- No cardiac history
Active Management Required
Do not simply document risk factors - actively manage them before and during Icotyde therapy 1. This means:
- Optimize blood pressure control
- Achieve glycemic targets in diabetics
- Initiate statin therapy for dyslipidemia
- Counsel on smoking cessation
- Recommend weight loss for obesity
Critical Caveat
The FDA label for Icotyde does not specifically mention cardiac risk assessment 3, as it is indicated for psoriasis, not cancer. However, because Icotyde modulates the immune system, applying cardio-oncology risk assessment principles is clinically prudent to identify patients who may develop cardiovascular complications during therapy. The evidence shows that cardiometabolic comorbidities independently increase cardiovascular adverse event risk with immune-modulating agents 4.
What NOT to Do
Do not initiate Icotyde in patients with: